You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FLT3-mutated high-risk myelodysplastic syndrome

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Decitabine and Cedazuridine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 19, 2022

Acute Myeloid Leukemia, MDS Trial (idarubicin, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • (no location specified)
Sep 18, 2023

Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +2 more
  • VEN+AZA+Modified BUCY
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 10, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Tumor Trial in Houston (Azacitidine, Quizartinib)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
May 23, 2022

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023

MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 30, 2023

High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston

Completed
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Daratumumab
  • Houston, Texas
    M D Anderson Cancer Center
Nov 21, 2022

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)

Active, not recruiting
  • Myelodysplastic Syndrome (MDS)
  • Brasschaat, Belgium
  • +9 more
Jan 19, 2023

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk

Recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +5 more
  • Gemtuzumab Ozogamicin
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)

Recruiting
  • Myelodysplastic Syndromes, de Novo
  • +10 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 23, 2023

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)
  • Durham, North Carolina
  • +8 more
Dec 13, 2022

Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial

Recruiting
  • Recurrent Chronic Myelomonocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

MDS, Acute Myeloid Leukemia Trial in New Haven (AG-120, Nivolumab)

Withdrawn
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • New Haven, Connecticut
    Yale Cancer Center
Jan 6, 2022

Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Los Angeles

Not yet recruiting
  • Clonal Cytopenia of Undetermined Significance
  • +4 more
  • Biospecimen Collection
  • +6 more
  • Los Angeles, California
  • +1 more
Oct 4, 2023

MDS Trial in Miami, New York (50 gm CIVI/24 hours x 5 days every 4 week)

Recruiting
  • Myelodysplastic Syndromes
  • 50 gm CIVI/24 hours x 5 days every 4 week
  • Miami, Florida
  • +1 more
Jul 6, 2022

FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia Trial in Houston

Active, not recruiting
  • FLT3 Gene Mutation Negative
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
Has Results
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte, New York, Houston (BTX-A51)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Duarte, California
  • +2 more
Sep 8, 2022

AML, Adult Recurrent, MDS Trial in United States (LYT-200)

Recruiting
  • AML, Adult Recurrent
  • MDS
  • Los Angeles, California
  • +13 more
Apr 12, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022